Trial Profile
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Dec 2015 New trial record